Vivos Therapeutics, Inc. - נכסים נקיים למניה בודדת VVOS

Vivos Therapeutics (VVOS) develops dental systems to combat apnea in US laboratories, yet its device assembly plants are operating strictly according to plan. The expected book value per share on the consolidated chart at GURU.Markets resolves this contradiction, with the indicator currently at -0.34. Strict FDA regulations and unique patents ensure business stability, creating significant barriers to entry for new players.

To isolate fundamental stability from market noise, it is essential to analyze the difference between total assets and liabilities distributed across the number of shares. The trend in the net book value per share reflects real capital accumulation, which is critical for Vivos Therapeutics (VVOS) amid geopolitical risks and the complexities of medical equipment certification in closed foreign markets.